CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

A total of 300 eligible subjects will be randomized in a 1:1 ratio to receive either convalescent plasma (CP) from people who have recovered from COVID-19 containing antibodies to SARS-CoV-2 or a placebo control, Lactated Ringer's Solution (LR) or saline solution (SS). Hospitalized COVID-19 patients aged ≥18 years of age with respiratory symptoms within 3 to 7 days from the onset of illness OR within 3 days of hospitalization will be eligible to participate.

Inclusion criteria

• Patients ≥18 years of age
• Hospitalized with laboratory confirmed COVID-19
• One or more of the following respiratory signs or symptoms: cough, chest pain, shortness of breath, fever, oxygen saturation ≤ 94%, abnormal CXR/CT imaging)
• Hospitalized for ≤ 72 hours OR within day 3 to 7 days from first signs of illness
• On supplemental oxygen, non-invasive ventilation or high-flow oxygen
• Patients may be on other randomized controlled trials of pharmaceuticals for COVID -19 and patients who meet eligibility criteria will not be excluded on this basis.

Exclusion criteria

• Receipt of pooled immunoglobulin in past 30 days
• Contraindication to transfusion or history of prior reactions to transfusion blood products
• Invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
• Volume overload secondary to congestive heart failure or renal failure
• Unlikely to survive past 72 hours from screening based on the assessment of the investigator
• Unlikely to be able to assess and follow outcome due to poor functional status